Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide vs Alendronate in Glucocorticoid-Induced Osteoporosis
NCT00051558Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2002
- Primary completion
- Jul 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of teriparatide in glucocorticoid-induced osteoporosis (GIOP) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD). Started Nov 2002; status: completed.
02
Drugs
teriparatide
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT00051558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051558.